Department of Orthopedic Surgery, Third Hospital of Hebei Medical University, 139 Ziqiang Road, Shijiazhuang, 050051, China.
Inflammopharmacology. 2021 Aug;29(4):1091-1099. doi: 10.1007/s10787-021-00828-5. Epub 2021 Jun 28.
This randomized, controlled study compared the efficacy and safety between oxycodone-paracetamol tablet and celecoxib for postoperative analgesia in patients who underwent arthroscopic knee surgery (AKS). Totally, 232 patients scheduled to undergo AKS were enrolled and were randomly assigned to either the oxycodone-paracetamol (OPT group) or the celecoxib group (CEL group). Pain at rest/motion (based on pain visual analog scale (VAS) score), rescue analgesia consumption, satisfaction level and adverse events were assessed after AKS. Pain VAS score at rest was decreased at 6 h, 12 h post-AKS in the OPT group compared with the CEL group. Similarly, pain VAS score at motion was reduced at 6 h, 12 h, 24 h post-AKS in the OPT group compared to the CEL group. Furthermore, both rescue analgesia rate (14.7% vs. 33.6%) and accumulated pethidine consumption (3.7 ± 8.9 mg vs. 14.0 ± 21.2 mg) were lower in OPT group compared with the CEL group. Patients satisfaction score was either at 24 h, 48 h in OPT group compared with the CEL group. Further subgroup analyses indicated that the effect of oxycodone-paracetamol versus (vs. celecoxib) on post-AKS management was more apparent in the elderly patients and male patients. In addition, the adverse events were well tolerable (including nausea, constipation, vomiting, drowsiness and dizziness) and were of no different between the two groups. In conclusion, oxycodone-paracetamol tablet presents increased analgesic efficacy for acute postoperative pain, with higher patient satisfaction and comparable safety profiles compared with celecoxib in patients underwent AKS.
本随机对照研究比较了曲马多-对乙酰氨基酚片和塞来昔布用于行关节镜膝关节手术(AKS)患者术后镇痛的疗效和安全性。共纳入 232 例拟行 AKS 的患者,随机分为曲马多-对乙酰氨基酚(OPT 组)或塞来昔布(CEL 组)。术后评估静息/运动时疼痛(基于疼痛视觉模拟评分(VAS)评分)、补救性镇痛药物消耗、满意度水平和不良事件。与 CEL 组相比,OPT 组术后 6 小时和 12 小时静息时的疼痛 VAS 评分降低。同样,OPT 组术后 6 小时、12 小时和 24 小时运动时的疼痛 VAS 评分均低于 CEL 组。此外,OPT 组的补救性镇痛药物使用率(14.7%比 33.6%)和累积哌替啶消耗量(3.7±8.9mg 比 14.0±21.2mg)均低于 CEL 组。与 CEL 组相比,OPT 组在术后 24 小时和 48 小时的患者满意度评分均较高。进一步的亚组分析表明,与塞来昔布相比,曲马多-对乙酰氨基酚对术后 AKS 管理的疗效在老年患者和男性患者中更为明显。此外,不良反应均耐受良好(包括恶心、便秘、呕吐、嗜睡和头晕),两组间无差异。总之,与塞来昔布相比,曲马多-对乙酰氨基酚片在 AKS 患者中具有更强的镇痛效果,更高的患者满意度和相似的安全性。